GlaxoSmithKline & Pfizer Joint Venture Awaits EU Clearance

By John Heerdink LinkedIn
Last year December, GlaxoSmithKline announced a deal or joint venture with Pfizer's consumer health business. The joint venture was expected to put them in an enviable competitive position in relation to its rivals like Johnson & Johnson, Bayer, and Sanofi. Recently, GlaxoSmithKline offered concessions to address EU’s antitrust concerns on the above venture. The European Commission is due to make a decision by July 10 either on the acceptance of the proposal or to proceed for a full-scale investigation. Dow 30 component Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Stay Informed! Stay Competitive! Join us at Vista Partners! It’s FREE to receive email updates.
  June 18 (5)

GSK offers concessions to address EU concerns over Pfizer deal
Read Full Article
(Read Original Story: )


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us